Added to YB: 2026-09-24
Pitch date: 2026-09-20
IOVA [bullish]
Iovance Biotherapeutics, Inc.
-2.3%
current return
Author Info
No bio for this author
Company Info
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.
Market Cap
$4.6B
Pitch Price
$10.43
Price Target
15.00 (+41%)
Dividend
N/A
EV/EBITDA
-17.91
P/E
-14.52
EV/Sales
13.51
Sector
Biotechnology
Category
growth
Sunday Week Ahead: September 21–27, 2026 - Iovance Biotherapeutics, Inc.
IOVA: Iovance’s thesis has shifted from proving Amtagvi can sell to determining how far TIL therapy can expand beyond melanoma: Q2 revenue was ~$99M, including ~$91M of U.S. Amtagvi sales, at a 56% gross margin. At $10.22, Barclays’ $15 bull target frames the upside ahead of Q3 demand commentary and Q4 lung data; start small and add on dips, given the recent run and single-product concentration.
Read full article (1 min)